- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Many clinical trial results not shared, finds study
19 February 2016 • Author: Victoria White
According to a new study, less than 40% of the results of clinical trials conducted at leading academic medical centres were shared within two years of completion.
“Not only was performance poor, but there was significant variation across the academic medical centers we studied,” said Dr Nihar Desai, assistant professor of medicine, section of cardiology at Yale School of Medicine and a researcher at the Yale Centre for Outcomes Research and Evaluation.
Randomised clinical trials are the gold standard in terms of testing the efficacy and safety of drugs, devices, and treatment strategies, so disseminating the results is of vital importance.
“Researchers also have an ethical responsibility to the patients enrolled in the study to make the results available,” he said. “Providers and patients will never be able to make evidence-based health care decisions if the data is not in the public domain. In addition, future research cannot benefit from what other researchers have already done if results are not reported and/or published in a timely fashion.”
Desai and colleagues previously studied the rates of results reporting and publication of clinical trials sponsored by the US National Institutes of Health (NIH) and by pharmaceutical companies. They decided to extend that prior work by looking at the dissemination of clinical trial results across leading academic institutions. The team reviewed over 4,300 clinical trials and examined how many were published or had results reported on ClinicalTrials.gov within 24 months of the studies’ completion.
Some institutions only disseminated 16% of their clinical trial results
The team saw variation in performance, with some institutions disseminating 16% of their completed clinical research, while others disseminated 55%.
“This is yet another blind spot in the clinical research enterprise, and we hope our findings will serve as a call to action,” said Desai. “Academic medical centres are uniquely positioned to lead this effort. They are dedicated to generating knowledge to improve health and health care. We hope our study will lead to a renewed commitment to our professional values and the mission of academic centres to not only conduct rigorous scientific investigation, but to share the results in a timely and transparent fashion.”
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics